This was the stock's second consecutive day of losses.

Last month, Regeneron had agreed to buy the firm for $256 million, beating an earlier $146 million bid from Wojcicki and the ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

GREENVILLE, S.C. (FOX Carolina/AP) - South Carolina is one of 27 states to join a lawsuit to block the sale of 23andMe users’ ...

Tesla ( TSLA) was the best-performing stock in the S&P 500 as the feud between CEO Elon Musk and President Donald Trump that ...

Kenvue Inc.'s stock had its worst day in nearly two years on Tuesday, as the maker of Band-Aids, Benadryl and Tylenol said tariffs, persistent inflation and weaker demand for allergy medicine, due to ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).

This mixed outcome, combined with unmet high expectations for the drug’s performance, triggered a sharp sell-off ... looking for an AI stock that is more promising than REGN and that has ...